INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2023. The put-call ratio across all filers is 2.22 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,518 | -41.8% | 564,549 | 0.0% | 1.00% | -34.3% |
| Q1 2024 | $4,324 | +79.8% | 564,549 | 0.0% | 1.53% | +66.4% |
| Q4 2023 | $2,405 | +26.1% | 564,549 | +24.3% | 0.92% | +26.2% |
| Q3 2023 | $1,907 | +55.7% | 454,008 | +106.4% | 0.73% | +49.2% |
| Q2 2023 | $1,225 | +33.6% | 220,000 | +37.5% | 0.49% | +35.6% |
| Q1 2023 | $917 | – | 160,000 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $34,430,559 | 22.13% |
| Affinity Asset Advisors, LLC | 2,642,519 | $20,241,696 | 2.51% |
| Blue Owl Capital Holdings LP | 1,270,027 | $9,728,407 | 1.94% |
| Samsara BioCapital, LLC | 1,562,500 | $11,968,750 | 1.85% |
| Sofinnova Investments, Inc. | 4,280,308 | $32,787,159 | 1.83% |
| Exome Asset Management LLC | 273,413 | $2,094,344 | 1.79% |
| Knott David M Jr | 564,549 | $4,324 | 1.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,372,907 | $10,516,468 | 1.48% |
| NEA Management Company, LLC | 2,437,689 | $18,672,698 | 1.16% |
| Rock Springs Capital Management LP | 3,681,174 | $28,197,793 | 0.72% |